Positive cardiac inotrope omecamtiv mecarbil activates muscle despite suppressing the myosin working stroke
Sign Up to like & getrecommendations! Published in 2018 at "Nature Communications"
DOI: 10.1038/s41467-018-06193-2
Abstract: Omecamtiv mecarbil (OM) is a positive cardiac inotrope in phase-3 clinical trials for treatment of heart failure. Although initially described as a direct myosin activator, subsequent studies are at odds with this description and do… read more here.
Keywords: omecamtiv mecarbil; myosin; cardiac inotrope; working stroke ... See more keywords
IMPLEMENTATION OF EVIDENCE-BASED INTERVENTIONS ACCORDING TO THE SWEDISH NATIONAL GUIDELINES FOR STROKECARE: A NATIONWIDE SURVEY AMONG PHYSIOTHERAPISTS
Sign Up to like & getrecommendations! Published in 2024 at "Journal of Rehabilitation Medicine"
DOI: 10.2340/jrm.v56.18444
Abstract: Objective To investigate (i) to what extent physiotherapists (PTs) working in stroke rehabilitation in various parts of the stroke care chain have implemented interventions according to the national guidelines for stroke (NGS), (ii) facilitating and… read more here.
Keywords: care; working stroke; evidence based; rehabilitation ... See more keywords
Myosin with hypertrophic cardiac mutation R712L has a decreased working stroke which is rescued by omecamtiv mecarbil
Sign Up to like & getrecommendations! Published in 2021 at "eLife"
DOI: 10.7554/elife.63691
Abstract: Hypertrophic cardiomyopathies (HCMs) are the leading cause of acute cardiac failure in young individuals. Over 300 mutations throughout β-cardiac myosin, including in the motor domain, are associated with HCM. A β-cardiac myosin motor mutation (R712L)… read more here.
Keywords: myosin; mutation r712l; working stroke;